Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study.

Bingham, Clifton O; Black, Shawn; Shiff, Natalie J; Xu, Stephen; Langholff, Wayne; Curtis, Jeffrey R

Bingham, Clifton O; Black, Shawn; Shiff, Natalie J; Xu, Stephen; Langholff, Wayne; Curtis, Jeffrey R.

Afiliação

Bingham CO; Johns Hopkins Division of Rheumatology, Johns Hopkins University, 5200 Eastern Ave, MFL Center Tower, Room 434A, Baltimore, MD, 21224, USA. cbingha2@jhmi.edu.
Black S; Department of Immunology, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Shiff NJ; Department of Immunology, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Xu S; Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Langholff W; Department of Biostatistics, Janssen Research & Development, Spring House, PA, USA.
Curtis JR; Department of Biostatistics, Janssen Research & Development, Spring House, PA, USA.

Rheumatol Ther ; 10(3): 659-678, 2023 Jun.

Article em En | MEDLINE | ID: mdl-36820983

Palavras-chave

Depression; Fatigue; Infliximab; Intravenous golimumab; Observational study; PROMIS; Pain interference; Patient-reported outcomes; Physical function; Rheumatoid arthritis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Rheumatol Ther Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google